A Phase 1 interventional study of maridebart cafraglutide and Placebo in Obesity, sponsored by Amgen. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-10.
Sponsored by Amgen · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.
Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 22nd largest by enrollment, is the only one that started in 2020, is one of 14 in phase 1, and was the 1st registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–70
Amgen · Sites in United States, Canada
Ages 18+
Amgen · Sites in United States, Puerto Rico
Ages 18–99
Amgen · Sites in United States, Canada, Japan and 2 more countries
Ages 18–99
Amgen · Sites in United States, Australia, Canada and 2 more countries
Ages 18–99
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 1 started in 2020.
This study's enrollment of 110 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 275 across the 28 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 28 have an industry lead sponsor. The 1 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
32 studies in Obesity by Amgen: 9 open now, 17 under way, 11 of them phase 3. Of 15 finished, 3 (20%) have results posted.
Among the 32 studies in Obesity by Amgen, this one is the 22nd largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2020, is one of 17 in phase 1, and was the 3rd registered.
Amgen’s Obesity studies by the year they started, since 2018.
9 of the studies testing maridebart cafraglutide in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07871409Phase 3AmgenHome Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | 2027-06-16 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 28 studies testing maridebart cafraglutide in Obesity, from their registry updates:
Among Amgen’s 32 in Obesity:
This tab as a report to print or save as PDF → With an account.
The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females must be of nonreproductive potential
Age \< 55 years with no menses for at least 12 months AND with a follicle-stimulating hormone level > 40 IU/L or according to the definition of "postmenopausal range" for the laboratory involved; OR
Exclusion Criteria:
Use of the following agents are excluded unless there is a prior consultation between the investigator and Amgen medical monitor:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
Biological: maridebart cafraglutide
Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
Drug: Placebo
Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
Biological: maridebart cafraglutide
Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
Drug: Placebo
Up to 2 open-label, multiple ascending dose cohorts (cohorts 12 to 13) treated with doses previously studied in Part A and Part B.
Biological: maridebart cafraglutide
Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.
Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE was defined as any adverse event (AE) which started on or after the first dose of AMG 133. Clinically significant changes in laboratory safety tests, vital signs and 12-lead electrocardiograms (ECGs) were included as AEs.
Time frame: Part A: 150 days; Part B: 207 days; Part C Cohort 12: 193 days; Part C Cohort 13: 207 days
Part A: Maximum Observed Concentration (Cmax) of AMG 133
The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.
Time frame: Cohort 1-5, 11: Day 1 predose and 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 7, 8, 15, 22, 29, 43, 57, 71, 92, 120 and 150. Cohort 6: Day 1 predose and 10 mins, 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 15, 22, 29, 43, 57, 71, 92, 120 and 150
Part B: Cmax of AMG 133
The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported.
Time frame: Cohorts 7-9: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 61, 63, 71, 78, 85, 127, 169 and 207. Cohort 10: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 63, 71, 78, 85, 169 and 207
Part A: Time of Maximum Observed Concentration (Tmax) of AMG 133
The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.
Time frame: Cohort 1-5, 11: Day 1 predose and 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 7, 8, 15, 22, 29, 43, 57, 71, 92, 120 and 150. Cohort 6: Day 1 predose and 10 mins, 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 15, 22, 29, 43, 57, 71, 92, 120 and 150
Part B: Tmax of AMG 133
The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported.
Time frame: Cohorts 7-9: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 61, 63, 71, 78, 85, 127, 169 and 207. Cohort 10: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 63, 71, 78, 85, 169 and 207
Part A: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of AMG 133
The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.
Time frame: Cohort 1-5, 11: Day 1 predose and 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 7, 8, 15, 22, 29, 43, 57, 71, 92, 120 and 150. Cohort 6: Day 1 predose and 10 mins, 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 15, 22, 29, 43, 57, 71, 92, 120 and 150
Part B: AUC From Day 0 to 28 (AUC0-28) of AMG 133
The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported. This parameter shows the AUC over the 28-day dosing interval, both from Day 1 to Day 29 (predose) and from Day 57 to Day 85.
Time frame: Cohorts 7-9: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 57 (predose), 61, 63, 71, 78 and 85. Cohort 10: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 57 (predose), 63, 71, 78 and 85
Percentage of Participants With Anti-AMG 133 Antibody Formation
The percentage of participants who developed anti-AMG 133 antibodies (binding and if positive, neutralizing to native GLP-1, when available) at any time was presented.
Time frame: Part A Cohort 1-6 and 11: Up to Day 150. Part B Cohort 7-10 and Part C Cohort 13: Up to Day 207. Part C Cohort 12: Up to Day 193
A total of 110 participants were enrolled into this trial in the United States between August 2020 and November 2022.
| Milestone | Part A SAD Cohort 1 AMG 133 | Part A SAD Cohort 2 AMG 133 | Part A SAD Cohort 3 AMG 133 | Part A SAD Cohort 4 AMG 133 | Part A SAD Cohort 5 AMG 133 | Part A SAD Cohort 6 AMG 133 | Part A SAD SC Placebo (Cohorts 1-5, 11) | Part A SAD IV Placebo (Cohort 6) | Part B MAD Cohort 7 AMG 133 | Part B MAD Cohort 8 AMG 133 | Part B MAD Cohort 9 AMG 133 | Part B MAD Cohort 10 AMG 133 | Part B MAD Cohorts 7-9 Placebo | Part B MAD Cohort 10 Placebo | Part A SAD Cohort 11 AMG 133 | Part C MAD Cohort 12 | Part C MAD Cohort 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 7 | 6 | 6 | 6 | 12 | 2 | 6 | 6 | 8 | 10 | 6 | 3 | 6 | 6 | 8 |
| Completed | 6 | 5 | 5 | 6 | 5 | 5 | 11 | 2 | 5 | 5 | 3 | 5 | 5 | 3 | 5 | 6 | 4 |
| Not completed | 0 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 5 | 5 | 1 | 0 | 1 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent from study | 0 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 4 | 3 | 0 | 0 | 1 | 0 | 4 |
The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.
| µg/mL | Part A SAD Cohort 1 AMG 133 | Part A SAD Cohort 2 AMG 133 | Part A SAD Cohort 3 AMG 133 | Part A SAD Cohort 4 AMG 133 | Part A SAD Cohort 5 AMG 133 | Part A SAD Cohort 6 AMG 133 | Part A SAD Cohort 11 AMG 133 |
|---|---|---|---|---|---|---|---|
| Intact AMG 133 | 1.31 ± 0.559 | 3.42 ± 1.18 | 6.09 ± 2.80 | 15.7 ± 11.4 | 35.8 ± 10.3 | 22.7 ± 4.10 | 41.5 ± 7.35 |
| Total AMG 133 | 1.43 ± 0.614 | 3.68 ± 1.16 | 6.78 ± 3.16 | 17.1 ± 11.8 | 37.7 ± 12.5 | 22.9 ± 4.21 | 43.2 ± 7.07 |
The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported.
| µg/mL | Part B MAD Cohort 7 AMG 133 | Part B MAD Cohort 8 AMG 133 | Part B MAD Cohort 9 AMG 133 | Part B MAD Cohort 10 AMG 133 |
|---|---|---|---|---|
| Intact AMG 133 after dosing on Day 1 | 8.30 ± 2.59 | 14.5 ± 5.99 | 27.4 ± 12.4 | 17.8 ± 5.32 |
| Total AMG 133 after dosing on Day 1 | 8.75 ± 2.56 | 16.2 ± 6.52 | 30.1 ± 12.3 | 18.8 ± 5.15 |
| Intact AMG 133 after dosing on Day 57 | 10.4 ± 2.19 | 21.9 ± 6.47 | 65.1 ± 20.4 | 27.2 ± 5.20 |
| Total AMG 133 after dosing on Day 57 | 13.1 ± 2.86 | 27.1 ± 8.12 | 80.8 ± 23.2 | 33.2 ± 6.77 |
The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.
| days | Part A SAD Cohort 1 AMG 133 | Part A SAD Cohort 2 AMG 133 | Part A SAD Cohort 3 AMG 133 | Part A SAD Cohort 4 AMG 133 | Part A SAD Cohort 5 AMG 133 | Part A SAD Cohort 6 AMG 133 | Part A SAD Cohort 11 AMG 133 |
|---|---|---|---|---|---|---|---|
| Intact AMG 133 | 5.0 (2.9 to 6.9) | 4.9 (3.9 to 6.9) | 6.0 (5.0 to 13) | 5.8 (2.8 to 13) | 3.9 (2.9 to 6.9) | 0.025 (0.0049 to 0.044) | 5.4 (1.9 to 6.0) |
| Total AMG 133 | 5.9 (4.0 to 6.9) | 4.9 (3.9 to 14) | 7.0 (6.0 to 13) | 6.9 (3.8 to 21) | 4.4 (2.9 to 6.9) | 0.043 (0.0049 to 0.044) | 5.9 (1.9 to 6.0) |
The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported.
| days | Part B MAD Cohort 7 AMG 133 | Part B MAD Cohort 8 AMG 133 | Part B MAD Cohort 9 AMG 133 | Part B MAD Cohort 10 AMG 133 |
|---|---|---|---|---|
| Intact AMG 133 after dosing on Day 1 | 5.9 (3.8 to 6.2) | 6.0 (4.1 to 14) | 5.9 (3.9 to 15) | 4.0 (3.8 to 7.0) |
| Total AMG 133 after dosing on Day 1 | 6.0 (3.8 to 6.2) | 6.0 (4.1 to 14) | 5.9 (3.9 to 15) | 4.0 (3.8 to 14) |
| Intact AMG 133 after dosing on Day 57 | 4.7 (4.1 to 15) | 4.3 (3.7 to 6.0) | 4.1 (4.0 to 5.1) | 6.0 (6.0 to 6.0) |
| Total AMG 133 after dosing on Day 57 | 5.6 (4.1 to 7.2) | 6.2 (3.7 to 14) | 4.1 (4.0 to 5.1) | 6.0 (6.0 to 6.0) |
The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.
| mcg*day/mL | Part A SAD Cohort 1 AMG 133 | Part A SAD Cohort 2 AMG 133 | Part A SAD Cohort 3 AMG 133 | Part A SAD Cohort 4 AMG 133 | Part A SAD Cohort 5 AMG 133 | Part A SAD Cohort 6 AMG 133 | Part A SAD Cohort 11 AMG 133 |
|---|---|---|---|---|---|---|---|
| Intact AMG 133 | 39.0 ± 13.6 | 108 ± 35.2 | 230 ± 56.2 | 442 ± 263 | 762 ± 196 | 205 ± 67.9 | 1150 ± 280 |
| Total AMG 133 | 56.4 ± 20.3 | 151 ± 51.2 | 300 ± 104 | 629 ± 375 | 1100 ± 321 | 264 ± 112 | 1720 ± 468 |
The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported. This parameter shows the AUC over the 28-day dosing interval, both from Day 1 to Day 29 (predose) and from Day 57 to Day 85.
| mcg*day/mL | Part B MAD Cohort 7 AMG 133 | Part B MAD Cohort 8 AMG 133 | Part B MAD Cohort 9 AMG 133 | Part B MAD Cohort 10 AMG 133 |
|---|---|---|---|---|
| Intact AMG 133 after dosing on Day 1 up to Day 29 | 149 ± 23.5 | 246 ± 95.5 | 594 ± 201 | 347 ± 28.7 |
| Total AMG 133 after dosing on Day 1 up to Day 29 | 181 ± 26.0 | 300 ± 122 | 697 ± 244 | 419 ± 43.7 |
| Intact AMG 133 after dosing on Day 57 up to Day 85 | 214 ± 18.7 | 443 ± 136 | 1220 ± 432 | 512 ± 79.7 |
| Total AMG 133 after dosing on Day 57 up to Day 85 | 297 ± 27.7 | 599 ± 224 | 1610 ± 624 | 691 ± 114 |
A TEAE was defined as any adverse event (AE) which started on or after the first dose of AMG 133. Clinically significant changes in laboratory safety tests, vital signs and 12-lead electrocardiograms (ECGs) were included as AEs.
| participants | Part A SAD Cohort 1 AMG 133 | Part A SAD Cohort 2 AMG 133 | Part A SAD Cohort 3 AMG 133 | Part A SAD Cohort 4 AMG 133 | Part A SAD Cohort 5 AMG 133 | Part A SAD Cohort 6 AMG 133 | Part A SAD SC Placebo (Cohorts 1-5, 11) | Part A SAD IV Placebo (Cohort 6) | Part B MAD Cohort 7 AMG 133 | Part B MAD Cohort 8 AMG 133 | Part B MAD Cohort 9 AMG 133 | Part B MAD Cohort 10 AMG 133 | Part B MAD Cohorts 7-9 Placebo | Part B MAD Cohort 10 Placebo | Part A SAD Cohort 11 AMG 133 | Part C MAD Cohort 12 | Part C MAD Cohort 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 0 | 2 | 5 | 6 | 5 | 6 | 3 | 1 | 6 | 6 | 8 | 8 | 3 | 0 | 6 | 5 | 6 |
The percentage of participants who developed anti-AMG 133 antibodies (binding and if positive, neutralizing to native GLP-1, when available) at any time was presented.
| percentage of participants | Part A SAD Cohort 1 AMG 133 | Part A SAD Cohort 2 AMG 133 | Part A SAD Cohort 3 AMG 133 | Part A SAD Cohort 4 AMG 133 | Part A SAD Cohort 5 AMG 133 | Part A SAD Cohort 6 AMG 133 | Part B MAD Cohort 7 AMG 133 | Part B MAD Cohort 8 AMG 133 | Part B MAD Cohort 9 AMG 133 | Part B MAD Cohort 10 AMG 133 | Part A SAD Cohort 11 AMG 133 | Part C MAD Cohort 12 | Part C MAD Cohort 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Binding antibody positive | 16.7 | 50.0 | 28.6 | 33.3 | 16.7 | 16.7 | 0.0 | 33.3 | 25.0 | 30.0 | 33.3 | 16.7 | 12.5 |
| Neutralizing antibody positive | 0.0 | 0.0 | 0.0 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 | 0.0 | 0.0 |
Collected over All-cause mortality and serious adverse events, from enrollment to end of study; median duration (min, max) in months: 4.93 (0.13, 7.03). TEAEs from first dose of study drug until end of study; duration with median (min, max) in months: 4.93 (0.13, 7.03). TEAE time frame for Part A: 150 days; Part B: 207 days; Part C Cohort 12: 193 days; Part C Cohort 13: 207 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A SAD Cohort 1 AMG 133 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A SAD Cohort 2 AMG 133 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part A SAD Cohort 3 AMG 133 | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Part A SAD Cohort 4 AMG 133 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part A SAD Cohort 5 AMG 133 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part A SAD Cohort 6 AMG 133 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part A SAD SC Placebo (Cohorts 1-5, 11) | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Part A SAD IV Placebo (Cohort 6) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Part B MAD Cohort 7 AMG 133 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part B MAD Cohort 8 AMG 133 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part B MAD Cohort 9 AMG 133 | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Part B MAD Cohort 10 AMG 133 | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Part B MAD Cohorts 7-9 Placebo | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part B MAD Cohort 10 Placebo | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Part A SAD Cohort 11 AMG 133 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part C MAD Cohort 12 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part C MAD Cohort 13 | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Event | Part A SAD Cohort 1 AMG 133 | Part A SAD Cohort 2 AMG 133 | Part A SAD Cohort 3 AMG 133 | Part A SAD Cohort 4 AMG 133 | Part A SAD Cohort 5 AMG 133 | Part A SAD Cohort 6 AMG 133 | Part A SAD SC Placebo (Cohorts 1-5, 11) | Part A SAD IV Placebo (Cohort 6) | Part B MAD Cohort 7 AMG 133 | Part B MAD Cohort 8 AMG 133 | Part B MAD Cohort 9 AMG 133 | Part B MAD Cohort 10 AMG 133 | Part B MAD Cohorts 7-9 Placebo | Part B MAD Cohort 10 Placebo | Part A SAD Cohort 11 AMG 133 | Part C MAD Cohort 12 | Part C MAD Cohort 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/6 | 2/6 | 4/7 | 4/6 | 5/6 | 6/6 | 3/12 | 0/2 | 5/6 | 4/6 | 8/8 | 3/10 | 1/6 | 0/3 | 5/6 | 4/6 | 6/8 |
| ConstipationGastrointestinal disorders | 0/6 | 0/6 | 0/7 | 1/6 | 0/6 | 3/6 | 1/12 | 0/2 | 2/6 | 1/6 | 0/8 | 0/10 | 0/6 | 0/3 | 3/6 | 5/6 | 4/8 |
| VomitingGastrointestinal disorders | 0/6 | 1/6 | 4/7 | 5/6 | 5/6 | 2/6 | 0/12 | 0/2 | 4/6 | 5/6 | 6/8 | 7/10 | 0/6 | 0/3 | 4/6 | 2/6 | 2/8 |
| DyspepsiaGastrointestinal disorders | 0/6 | 1/6 | 4/7 | 0/6 | 0/6 | 3/6 | 1/12 | 0/2 | 1/6 | 0/6 | 1/8 | 0/10 | 0/6 | 0/3 | 0/6 | 0/6 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 2/12 | 0/2 | 1/6 | 0/6 | 2/8 | 2/10 | 0/6 | 0/3 | 0/6 | 3/6 | 1/8 |
| ChillsGeneral disorders | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 0/12 | 0/2 | 0/6 | 0/6 | 4/8 | 0/10 | 0/6 | 0/3 | 0/6 | 0/6 | 0/8 |
| HeadacheNervous system disorders | 0/6 | 1/6 | 3/7 | 1/6 | 0/6 | 2/6 | 1/12 | 1/2 | 1/6 | 2/6 | 1/8 | 3/10 | 3/6 | 0/3 | 1/6 | 1/6 | 3/8 |
| Early satietyGeneral disorders | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 2/6 | 0/12 | 0/2 | 0/6 | 0/6 | 0/8 | 0/10 | 0/6 | 0/3 | 0/6 | 0/6 | 0/8 |
| Decreased appetiteMetabolism and nutrition disorders | 0/6 | 0/6 | 1/7 | 0/6 | 0/6 | 2/6 | 0/12 | 0/2 | 1/6 | 0/6 | 0/8 | 0/10 | 0/6 | 0/3 | 1/6 | 1/6 | 0/8 |
| Taste disorderNervous system disorders | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 0/12 | 0/2 | 0/6 | 0/6 | 0/8 | 0/10 | 0/6 | 0/3 | 0/6 | 2/6 | 0/8 |
| Age, Categorical(Participants) | Part A SAD Cohort 1 AMG 133 | Part A SAD Cohort 2 AMG 133 | Part A SAD Cohort 3 AMG 133 | Part A SAD Cohort 4 AMG 133 | Part A SAD Cohort 5 AMG 133 | Part A SAD Cohort 6 AMG 133 | Part A SAD SC Placebo (Cohorts 1-5, 11) | Part A SAD IV Placebo (Cohort 6) | Part B MAD Cohort 7 AMG 133 | Part B MAD Cohort 8 AMG 133 | Part B MAD Cohort 9 AMG 133 | Part B MAD Cohort 10 AMG 133 | Part B MAD Cohorts 7-9 Placebo | Part B MAD Cohort 10 Placebo | Part A SAD Cohort 11 AMG 133 | Part C MAD Cohort 12 | Part C MAD Cohort 13 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 6 | 7 | 6 | 6 | 6 | 12 | 2 | 6 | 6 | 8 | 10 | 6 | 3 | 6 | 6 | 8 | 109 |
| >=65 years | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Part A SAD Cohort 1 AMG 133 | Part A SAD Cohort 2 AMG 133 | Part A SAD Cohort 3 AMG 133 | Part A SAD Cohort 4 AMG 133 | Part A SAD Cohort 5 AMG 133 | Part A SAD Cohort 6 AMG 133 | Part A SAD SC Placebo (Cohorts 1-5, 11) | Part A SAD IV Placebo (Cohort 6) | Part B MAD Cohort 7 AMG 133 | Part B MAD Cohort 8 AMG 133 | Part B MAD Cohort 9 AMG 133 | Part B MAD Cohort 10 AMG 133 | Part B MAD Cohorts 7-9 Placebo | Part B MAD Cohort 10 Placebo | Part A SAD Cohort 11 AMG 133 | Part C MAD Cohort 12 | Part C MAD Cohort 13 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 1 | 3 | 2 | 1 | 2 | 4 | 0 | 1 | 2 | 7 | 5 | 4 | 1 | 1 | 5 | 3 | 47 |
| Male | 1 | 5 | 4 | 4 | 5 | 4 | 8 | 2 | 5 | 4 | 1 | 5 | 2 | 2 | 5 | 1 | 5 | 63 |
| Ethnicity (NIH/OMB)(Participants) | Part A SAD Cohort 1 AMG 133 | Part A SAD Cohort 2 AMG 133 | Part A SAD Cohort 3 AMG 133 | Part A SAD Cohort 4 AMG 133 | Part A SAD Cohort 5 AMG 133 | Part A SAD Cohort 6 AMG 133 | Part A SAD SC Placebo (Cohorts 1-5, 11) | Part A SAD IV Placebo (Cohort 6) | Part B MAD Cohort 7 AMG 133 | Part B MAD Cohort 8 AMG 133 | Part B MAD Cohort 9 AMG 133 | Part B MAD Cohort 10 AMG 133 | Part B MAD Cohorts 7-9 Placebo | Part B MAD Cohort 10 Placebo | Part A SAD Cohort 11 AMG 133 | Part C MAD Cohort 12 | Part C MAD Cohort 13 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 1 | 1 | 0 | 0 | 5 | 2 | 2 | 4 | 4 | 10 | 2 | 3 | 5 | 1 | 2 | 45 |
| Not Hispanic or Latino | 5 | 4 | 6 | 5 | 6 | 6 | 7 | 0 | 4 | 2 | 4 | 0 | 4 | 0 | 1 | 5 | 6 | 65 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A SAD Cohort 1 AMG 133 | Part A SAD Cohort 2 AMG 133 | Part A SAD Cohort 3 AMG 133 | Part A SAD Cohort 4 AMG 133 | Part A SAD Cohort 5 AMG 133 | Part A SAD Cohort 6 AMG 133 | Part A SAD SC Placebo (Cohorts 1-5, 11) | Part A SAD IV Placebo (Cohort 6) | Part B MAD Cohort 7 AMG 133 | Part B MAD Cohort 8 AMG 133 | Part B MAD Cohort 9 AMG 133 | Part B MAD Cohort 10 AMG 133 | Part B MAD Cohorts 7-9 Placebo | Part B MAD Cohort 10 Placebo | Part A SAD Cohort 11 AMG 133 | Part C MAD Cohort 12 | Part C MAD Cohort 13 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 5 | 3 | 0 | 5 | 4 | 0 | 3 | 1 | 1 | 0 | 1 | 0 | 0 | 4 | 2 | 33 |
| White | 4 | 4 | 2 | 3 | 5 | 1 | 8 | 2 | 2 | 5 | 7 | 10 | 5 | 3 | 5 | 2 | 4 | 72 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Aug 2020 to primary completion in Nov 2022, 27 months.
Results were first posted in Dec 2025, 3 years after primary completion.
Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 27 months is above that.
Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maridebart cafraglutide